Cue Biopharma, Inc.

The momentum for this stock is not very good. Cue Biopharma, Inc. is not a good value stock. Cue Biopharma, Inc. is not very popular among insiders. Cue Biopharma, Inc. is a mediocre stock to choose.

Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and...

News

Cue Biopharma appoints Lucinda Warren as CBO

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Globe Newswire BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...\n more…

Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference

Globe Newswire BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...\n more…

Cue Biopharma (NASDAQ:CUE) Price Target Lowered to $4.00 at Stifel Nicolaus

Ticker Report Cue Biopharma (NASDAQ:CUE - Free Report) had its target price decreased by Stifel Nicolaus from $8.00 to $4.00 in a research report sent to investors on Tuesday, Benzinga reports. Stifel Nicolaus...\n more…

Oppenheimer Reaffirms Their Buy Rating on Cue Biopharma (CUE)

TipRanks Financial Blog In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Cue Biopharma (CUE - Research Report), with a price target ...\n more…

Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript

SeekingAlpha Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript...\n more…